Generic Name and Formulations:
Nitroglycerin 0.3mg, 0.4mg, 0.6mg; sublingual tabs.
Indications for NITROSTAT:
Acute relief of angina attack. Acute prophylaxis of angina pectoris.
Use lowest effective dose. Treatment: 1 tab sublingually or in buccal pouch at onset, may repeat in 5mins; max 3 tabs in 15mins. Prophylaxis: 5–10mins before activity.
Severe anemia. Increased intracranial pressure (eg, cerebral hemorrhage, traumatic brain injury). Acute circulatory failure or shock. Concomitant PDE-5 inhibitors (eg, avanafil, sildenafil, tadalafil, vardenafil), soluble guanylate cyclase stimulators (eg, riociguat).
Constrictive pericarditis, aortic or mitral stenosis, volume-depleted, hypotensive: increased risk of severe hypotension. Hypertrophic cardiomyopathy. Elderly. Pregnancy. Nursing mothers: not studied.
See Contraindications. Hypotension potentiated by PDE-5 inhibitors, riociguat. Avoid ergotamine and related drugs.
Headache, dizziness, paresthesia, vertigo, weakness, palpitation, postural hypotension, syncope, flushing, rash, exfoliative dermatitis.
Tabs 0.4mg—4 x 25, 100; 0.3mg, 0.6mg—100
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|